Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06768476 · ClinicalTrials.gov registry record · Phase 1
CART123 + Ruxolitinib in Relapsed/Refractory AML
A Phase 1 study of Refractory AML and Relapsed AML, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06768476 is a Phase 1 study of Refractory AML and Relapsed AML that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06768476, a Phase 1 study of Refractory AML and Relapsed AML, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I, open-label study to assess the safety, feasibility, pharmacokinetics, and preliminary efficacy of CART123 cells given in combination with ruxolitinib in patients with relapsed or refractory acute myeloid leukemia (AML). All subjects will receive a single infusion of CART123 cells following ruxolitinib administration and lymphodepletion. Ruxolitinib dosing will begin at initiation of lymphodepleting chemotherapy (Day -6 ±1d) and continue for up to 14 days post CART123 administration.
Conditions Studied
Interventions
- BIOLOGICAL CART123 Cells
- DRUG Ruxolitinib 10 MG
- DRUG Ruxolitinib 5 MG
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2045-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06768476
The ClinicalTrials.gov registry entry for NCT06768476 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory AML appearing as the primary indexed condition, and to 3 interventions - of which CART123 Cells is the first listed.
NCT06768476 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06768476 about?
NCT06768476 is a clinical study titled "CART123 + Ruxolitinib in Relapsed/Refractory AML". Phase I, open-label study to assess the safety, feasibility, pharmacokinetics, and preliminary efficacy of CART123 cells given in combination with ruxolitinib in patients with relapsed or refractory acute myeloid leukemia (AML). All subjects will receive a single infusion of CART123 cells following ...
What is the current status of trial NCT06768476?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-02-28. Estimated completion is 2045-03.
What conditions does trial NCT06768476 study?
This clinical trial studies the following conditions: Refractory AML, Relapsed AML.
What interventions are being tested in trial NCT06768476?
The interventions under investigation include: CART123 Cells (BIOLOGICAL), Ruxolitinib 10 MG (DRUG), Ruxolitinib 5 MG (DRUG).
Who is sponsoring clinical trial NCT06768476?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06768476 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.